Drug or treatment

Lenvatinib clinical trials

• 110Clinical trials
• 3New in 30 days
• 17Countries

Newest trials

All recruiting trials (110)

• Lenvatinib and Pembrolizumab With or Without SBRT for Metastatic Kidney Cancer

  This study tests whether adding SBRT to standard lenvatinib plus pembrolizumab helps people with metastatic kidney cancer who have stable disease after initial treatment.

  Recruiting at 8 sites Phase 2 Kidney Cancer Research Bureau · Kazan' and 7 other locations · NCT07928167

• Cadonilimab and Lenvatinib in advanced kidney cancer

  This study tests whether Cadonilimab plus Lenvatinib can help adults with unresectable, advanced renal cell carcinoma, especially clear cell type, after prior treatments.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Panjiayuan Nanli · NCT07909265

• MRG003 added to ongoing treatment after progression in EGFR-positive advanced thyroid cancer

  In this study, researchers test whether adding MRG003 to a patient’s current thyroid cancer treatment can shrink tumors for those whose cancer initially responded but later progressed.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07874321

• Cryoablation with liver-directed immunotherapy and targeted therapy for melanoma liver metastases

  This trial tests a combination therapy including cryoablation, hepatic artery delivery of QL1706, intravenous dacarbazine, and oral lenvatinib to treat liver metastases from malignant melanoma in adults.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07847359

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

• Lenvatinib plus chemotherapy for pancreatic neuroendocrine tumors with liver metastases

  This study tests whether adding lenvatinib to chemotherapy helps people with pancreatic neuroendocrine tumors that have spread to the liver, after first-line therapy has stopped working.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07835893

• Irreversible Electroporation Added to Targeted Therapy and Immunotherapy for Advanced HCC

  This study tests whether adding irreversible electroporation to lenvatinib and sintilimab can help patients with unresectable advanced hepatocellular carcinoma see bigger tumor shrinkage and become eligible for surgery.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, China · NCT07832006

• Iparomlimab and Tuvonralimab with SBRT and Lenvatinib for Potentially Resectable Intermediate-Stage HCC

  This trial tests whether adding two antibodies together with SBRT and lenvatinib can improve outcomes for adults with potentially resectable intermediate-stage hepatocellular carcinoma.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07801287

• Iparomlimab and Tuvonralimab with Lenvatinib, Radiotherapy, and HAIC in HCC with PVTT

  This trial tests a multi-drug approach to see if it can control liver cancer that has grown into the portal vein in adults.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07776080

• Trastuzumab Rezetecan with Adebrelimab and Lenvatinib for advanced HER2-positive/low-expression biliary tract cancer

  This study tests a triple therapy to see if it helps people with advanced biliary tract cancer that is HER2-positive or has low HER2 expression after at least one prior treatment.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07704177

• Adjuvant durvalumab with GEMOX/GC chemotherapy followed by lenvatinib vs capecitabine in biliary tract cancer after surgery

  This trial tests whether adding durvalumab with GEMOX/GC chemotherapy followed by lenvatinib after surgery helps biliary tract cancer patients stay cancer-free longer than capecitabine alone.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing · NCT07679399

• First-line treatment with Trastuzumab Rezetecan, Adebrelimab, and Lenvatinib for advanced HER2-positive or HER2-low biliary tract cancer

  This phase II trial tests whether a combination of Trastuzumab Rezetecan, Adebrelimab, and Lenvatinib can help people with advanced HER2-positive or HER2-low biliary tract cancer respond to treatment as a first line therapy.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing · NCT07670273

• First-line chemo with hepatic arterial infusion plus Envafolimab and Lenvatinib for unresectable biliary tract cancer

  This trial tests a first-line treatment combining hepatic arterial infusion chemotherapy with Envafolimab and Lenvatinib to see if it helps patients with unresectable biliary tract cancer.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07636798

• Pembrolizumab and Lenvatinib for recurrent endometrial cancer that has progressed after first-line therapy

  This trial tests a combination of pembrolizumab and lenvatinib to see if it can help adults with recurrent mismatch repair-proficient endometrial cancer after failure of initial platinum-based chemo and immunotherapy.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT07594015

• Perioperative toripalimab plus lenvatinib for multi-stage clear cell kidney cancer

  This trial tests whether giving toripalimab with lenvatinib before surgery helps shrink or kill tumors in people with localized, locally advanced, or metastatic clear cell kidney cancer.

  Recruiting Phase 2 Jinling Hospital, China · Nanjing, Jiangsu · NCT07571551

• Iparomlimab and Tuvonralimab with albumin‑bound paclitaxel and lenvatinib for second‑line advanced biliary tract cancer

  This trial tests whether adding two immune antibodies (Iparomlimab and Tuvonralimab) to paclitaxel and lenvatinib can help people with unresectable or metastatic biliary tract cancer whose disease progressed after one prior platinum‑based or gemcitabine-containing regimen.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou · NCT07530445

• Intensified versus conversion therapy for advanced liver cancer after first-line bevacizumab plus sintilimab fails

  This study tests whether adding lenvatinib or switching to regorafenib plus a PD-1 blocker works better and is safe for adults with advanced hepatocellular carcinoma whose cancer progressed after first-line bevacizumab plus sintilimab.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07501351

• Fostrox plus lenvatinib versus lenvatinib in advanced HCC after immunotherapy

  In people whose advanced liver cancer got worse after first-line immunotherapy, this study tests whether adding fostrox to lenvatinib helps more than lenvatinib alone.

  Recruiting Phase 2 CHA University · Seongnam-si, Gyeonggi-do · NCT07493668

• Conversion therapy with FOLFOX-HAIC, lenvatinib, and tislelizumab for HCC with VP3 PVTT

  This study tests a triple combination therapy to try to shrink tumors and PVTT in people with unresectable hepatocellular carcinoma to enable potential surgical removal.

  Recruiting Phase 2 First Hospital of China Medical University · Shenyang, Liaoning · NCT07483359

• Y90 liver radiation plus immunotherapy and targeted drug for unresectable liver cancer

  This test will see if adding Y90 liver radiation to nivolumab, ipilimumab, and lenvatinib helps people with unresectable hepatocellular carcinoma live longer and have better tumor responses.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07482059

• Neoadjuvant tislelizumab plus lenvatinib for resectable hepatocellular carcinoma at high risk of recurrence

  This trial tests whether giving tislelizumab and lenvatinib before surgery can reduce recurrence and improve outcomes in people with resectable hepatocellular carcinoma at high risk of coming back.

  Recruiting Phase 3 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07475026

• Lenvatinib plus PD-1 inhibitor for tumors with 11q13 amplification

  This trial tests whether combining lenvatinib with a PD-1 inhibitor can help adults with advanced solid tumors that have 11q13 gene amplification.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei and 1 other locations · NCT07417501

• TACE plus lenvatinib versus lenvatinib alone for unresectable liver cancer

  This trial will test whether adding transarterial chemoembolization (TACE) to lenvatinib helps people with unresectable hepatocellular carcinoma get better tumor responses than taking lenvatinib alone.

  Recruiting Bangladesh Medical University · Dhaka · NCT07408804

• Iparomlimab and Tuvonralimab plus lenvatinib before kidney-sparing surgery for clear cell kidney cancer

  This will test whether giving Iparomlimab and Tuvonralimab (QL1706) together with lenvatinib before surgery helps people with localized clear cell kidney cancer (T1–T2) who need but may have difficulty getting kidney-preserving surgery because of a high R.E.N.A.L. score.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou · NCT07389629

• QL1706 with lenvatinib for previously treated penile cancer

  This trial tests whether combining QL1706 with lenvatinib can help control advanced or metastatic penile squamous cell carcinoma in people whose disease progressed after prior treatments.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07384416

• Paclitaxel polymer micelles with gemcitabine and targeted drugs for advanced sarcoma

  This Phase 2 study tests whether combining a new paclitaxel formulation with gemcitabine and a targeted drug can help people with advanced or metastatic bone or soft tissue sarcoma that progressed after first-line chemotherapy.

  Recruiting Phase 2 Shanghai 6th People's Hospital · Shanghai, CH · NCT07359053

• Pembrolizumab plus lenvatinib for vulvar cancer (MITO VULVA-01)

  This trial will test whether combining pembrolizumab with lenvatinib helps people with advanced, recurrent, or unresectable vulvar cancer.

  Recruiting Phase 2 National Cancer Institute, Naples · Naples · NCT07290894

• Visugromab plus Nivolumab and Lenvatinib versus Placebo plus Lenvatinib for unresectable or metastatic hepatocellular carcinoma after anti–PD-(L)1 therapy

  This trial will test whether adding visugromab and nivolumab to lenvatinib helps people with unresectable or metastatic liver cancer whose disease progressed after an anti–PD-(L)1 treatment.

  Recruiting at 29 sites Phase 2 CatalYm GmbH · Irvine, California and 28 other locations · NCT07219459

• Pucotenlimab with lenvatinib and chemotherapy for children with advanced or relapsed hepatoblastoma

  This study will test whether pucotenlimab combined with lenvatinib and irinotecan can help children aged 2–18 whose hepatoblastoma did not respond to prior treatments.

  Recruiting Sun Yat-sen University · Guangdong, Guangzhou · NCT07188311

• Later-line paclitaxel polymer micelle plus immunotherapy for biliary tract cancer

  This trial tests whether giving a paclitaxel polymer micelle combined with immunotherapy helps people with advanced biliary tract cancer who have finished first-line treatment.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07159204

• Lenvatinib with nivolumab and chemotherapy for metastatic gastric cancer with malignant ascites

  This trial tests whether adding lenvatinib to nivolumab plus chemotherapy helps people with metastatic gastric or gastroesophageal junction adenocarcinoma who have peritoneal metastases and significant malignant ascites.

  Recruiting Phase 1/2 Asan Medical Center · Seoul · NCT07149090

• First-line QL1706 combined with lenvatinib and AG for advanced metastatic pancreatic cancer

  This trial will test whether combining QL1706, lenvatinib, and gemcitabine plus nab‑paclitaxel (AG) works better as first-line treatment for people with advanced metastatic pancreatic cancer who have not had prior therapy.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing · NCT07110064

• QL1706 (iparomlimab + tuvonralimab) with TACE and lenvatinib for second-line treatment of unresectable intermediate-to-advanced liver cancer

  This test will try whether adding QL1706 (iparomlimab plus tuvonralimab) to TACE and lenvatinib helps people with unresectable intermediate-to-advanced hepatocellular carcinoma who progressed after PD-1/PD-L1 plus bevacizumab.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07099274

• Lenvatinib for advanced GIST after imatinib, sunitinib, and regorafenib

  This trial tests whether the oral drug lenvatinib can help people with metastatic or advanced GIST whose disease has progressed on imatinib, sunitinib, and regorafenib.

  Recruiting Phase 1/2 Asan Medical Center · Seoul · NCT07096609

• 24 mg versus 10 mg daily lenvatinib for symptomatic or progressive radioactive iodine–resistant differentiated thyroid cancer

  This trial tests whether a higher (24 mg) or lower (10 mg) daily dose of lenvatinib works better and is easier to tolerate for people with symptomatic or progressive radioactive iodine–resistant differentiated thyroid cancer.

  Recruiting Phase 2 Washington University School of Medicine · St Louis, Missouri · NCT07092514

• Cryoablation with lenvatinib and QL1706 for advanced intrahepatic cholangiocarcinoma

  We will try freezing tumors (cryoablation) together with the drugs lenvatinib and QL1706 in people whose advanced intrahepatic cholangiocarcinoma has worsened after first-line treatment.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07070700

• Lenvatinib plus tislelizumab versus lenvatinib alone for advanced hepatocellular carcinoma after prior PD‑1/PD‑L1 plus bevacizumab

  This trial will test whether adding the immunotherapy tislelizumab to lenvatinib works better than lenvatinib alone for people with advanced liver cancer who progressed after prior PD‑1/PD‑L1 plus bevacizumab treatment.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07047586

• Pre-surgery treatment with iparomlimab, tuvonralimab, and lenvatinib for liver cancer

  This trial will try a 9-week pre-surgery combination of two immune antibodies (iparomlimab and tuvonralimab) plus daily lenvatinib in people with resectable hepatocellular carcinoma who are at high risk of recurrence.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07014150

• BL-B01D1 plus lenvatinib for advanced hepatocellular carcinoma

  This trial tests whether adding BL-B01D1 to lenvatinib helps people with advanced hepatocellular carcinoma shrink tumors or slow disease progression.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06986785

• Combining Lenvatinib with SIRT for Advanced Liver Cancer

  This study is testing whether combining a cancer drug called lenvatinib with a type of radiation therapy can help people with advanced liver cancer that hasn't improved with other treatments.

  Recruiting Phase 2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT06904196

• Combination treatment for large liver cancer with portal vein involvement

  This study is testing a new combination treatment for people with large liver cancer that has spread to the portal vein to see if it works better than the standard treatment.

  Recruiting Phase 2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT06904183

• Combining sintilimab, lenvatinib, and HAIC for treating borderline resectable liver cancer before surgery

  This study is testing if a combination of three treatments can help people with borderline resectable liver cancer do better in surgery compared to having surgery right away.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06904014

• Durvalumab + Tremelimumab with or without Lenvatinib for unresectable liver cancer

  This trial tests whether adding lenvatinib to the STRIDE regimen (durvalumab plus tremelimumab) helps people with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

  Recruiting at 13 sites Phase 2 Canadian Cancer Trials Group · Calgary, Alberta and 12 other locations · NCT06880523

• Combining cryoablation with lenvatinib and Tislelizumab for advanced intrahepatic cholangiocarcinoma

  This study is testing if a new treatment combining cryoablation, lenvatinib, and Tislelizumab can help people with advanced intrahepatic cholangiocarcinoma who haven't had success with other treatments feel better compared to standard chemotherapy.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06860477

• Combining HAIC with Durvalumab and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma

  This study is testing a new treatment combining chemotherapy with two other drugs to see if it can help people with advanced bile duct cancer feel better and live longer.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT06859684

• Combination treatment for advanced intrahepatic cholangiocarcinoma and gallbladder cancer

  This study is testing a new combination treatment for people with advanced bile duct and gallbladder cancer to see if it can help them respond better to therapy and possibly become eligible for surgery.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tia · NCT06852287

• Multimodal ablation with Tislelizumab, lenvatinib and TACE for unresectable primary liver cancer

  This trial will test whether combining multimodal ablation with Tislelizumab (a PD‑1 antibody), lenvatinib, and TACE helps people with unresectable primary liver cancer.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT06794073

• Effect of Lenvatinib on High-risk Liver Cancer Recurrence After Surgery

  This study is testing if the drug lenvatinib can help prevent liver cancer from coming back after surgery in patients at high risk for recurrence.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06762782

• Treatment for ruptured liver cancer using TACE, Lenvatinib, and PD-1 inhibitors

  This study is testing a new treatment that combines a special type of chemotherapy with Lenvatinib and PD-1 inhibitors to see if it can help patients with serious liver cancer that has ruptured.

  Recruiting Sun Yat-sen University · Beijing, None Selected · NCT06740370

• Combination therapy of pembrolizumab and lenvatinib for unresectable cutaneous angiosarcoma

  This study is testing if a combination of two drugs, pembrolizumab and lenvatinib, can help people with a type of skin cancer called unresectable cutaneous angiosarcoma who haven't had success with other treatments.

  Recruiting at 6 sites Phase 2 National Cancer Center, Japan · Kashiwa and 5 other locations · NCT06673628

• Lenvatinib plus pembrolizumab for anal or rectal cancer that progressed after first treatment

  This trial gives lenvatinib with pembrolizumab to people whose anorectal squamous cell cancer has spread or gotten worse after first-line chemotherapy or chemoradiation to see if the combination controls the cancer and is safe.

  Recruiting Phase 2 University of Chicago · Chicago, Illinois · NCT06669572

• Evaluating biomarkers in advanced biliary tract cancer treatment with lenvatinib and pembrolizumab

  This study is testing if a combination of two drugs, lenvatinib and pembrolizumab, can help people with advanced biliary tract cancer and is looking for clues in their genetic data to see how well the treatment works.

  Recruiting CHA University · Seongnam-si, Gyeonggi-do · NCT06648057

• Combining D-TACE-HAIC with Envafolimab and Lenvatinib for treating advanced liver cancer

  This study is testing a new treatment combining D-TACE-HAIC, Envafolimab, and Lenvatinib to see if it helps people with advanced liver cancer that can't be surgically removed.

  Recruiting Fujian Provincial Hospital · Fuzhou, Fujian · NCT06643208

• Combining TIPS with Lenvatinib and PD-1 inhibitors for advanced liver cancer with portal vein tumor thrombus

  This study is testing if combining a special procedure with two cancer treatments can help people with advanced liver cancer and a serious blood clot in the portal vein feel better and have better results.

  Recruiting Sun Yat-sen University · Beijing, None Selected · NCT06622031

• Comparing TACE-Lenvatinib with TACE-Lenvatinib-ablation for recurrent liver cancer

  This study is testing if adding ablation to the combination of TACE and Lenvatinib can help people with recurrent liver cancer feel better compared to just using TACE and Lenvatinib alone.

  Recruiting Sun Yat-sen University · Beijing, None Selected · NCT06609850

• Triple therapy for advanced liver cancer with bile duct tumor thrombus

  This study is testing a new combination treatment for people with advanced liver cancer that has spread to the bile ducts to see if it can help them when surgery isn't an option.

  Recruiting Fujian Provincial Hospital · Fuzhou, Fujian and 5 other locations · NCT06602011

• Using immune checkpoint inhibitors to preserve organs in non-metastatic gastric or colon cancers

  This study is testing a new combination of immune treatments to see if it can help people with non-metastatic gastric or colon cancers keep their organs and improve their health before surgery.

  Recruiting Phase 2 Peking University · Beijing, Beijing Municipality · NCT06580574

• Neoadjuvant triple therapy for liver cancer

  This study is testing a new combination treatment for liver cancer to see if it helps patients before they have surgery.

  Recruiting Fujian Provincial Hospital · Fuzhou, Fujian and 5 other locations · NCT06569498

• Triple therapy for patients with unresectable liver cancer

  This study is testing a new combination treatment for patients with hard-to-treat liver cancer to see if it can help shrink tumors more and improve survival rates.

  Recruiting Fujian Provincial Hospital · Fuzhou, Fujian and 3 other locations · NCT06561399

• Ablation combined with lenvatinib and PD-1 inhibitor for advanced liver cancer with limited metastases

  This study is testing if combining a targeted treatment with a special type of therapy can help people with advanced liver cancer that has spread a little, to see if it improves their chances of living longer.

  Recruiting Sun Yat-sen University · Beijing, None Selected · NCT06550921

• Combining lenvatinib with TACE and HAIC for large liver cancer with portal vein thrombosis

  This study is testing a new combination treatment for people with large liver cancer and blood clots in the portal vein to see if it works better than just one of the treatments alone.

  Recruiting Phase 3 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT06492395

• Neoadjuvant therapy for patients with resectable hepatocellular carcinoma using deep learning.

  This study is testing a new treatment plan using a combination of chemotherapy and other medications for patients with early-stage liver cancer to see if it helps them live longer and reduces the chances of the cancer coming back after surgery.

  Recruiting at 2 sites Phase 2 Tongji Hospital · Xiangyang, Hubei and 1 other locations · NCT06420440

• Treatment for advanced liver cancer using Cadonilimab and Lenvatinib

  This study is testing if a new combination of Cadonilimab, Lenvatinib, and chemotherapy can help people with advanced liver cancer that can't be surgically removed.

  Recruiting Phase 2 Hunan Cancer Hospital · Changsha, Hunan · NCT06406634

• Combining Pembrolizumab and Lenvatinib for Anaplastic Thyroid Cancer

  This study is testing if a combination of two drugs, pembrolizumab and lenvatinib, can help people with anaplastic thyroid cancer who haven't been treated before.

  Recruiting Phase 2 Saint Petersburg State University, Russia · Saint Petersburg · NCT06374602

• Combining AK104 and Lenvatinib with TACE for treating liver cancer

  This study is testing if combining two treatments, AK104 and lenvatinib, with a procedure called TACE can help people with liver cancer who can't have surgery feel better compared to just having TACE alone.

  Recruiting at 4 sites Phase 3 Akeso · Zhengzhou, Henan and 3 other locations · NCT06371157

• Combining chemotherapy and targeted therapy for advanced liver cancer

  This study is testing whether combining a specific type of chemotherapy with two targeted therapies can help people with advanced liver cancer feel better and improve their treatment results.

  Recruiting Sun Yat-sen University · Beijing, Beijing Municipality · NCT06333561

• Combined therapy for advanced intrahepatic cholangiocarcinoma

  This study is testing a new combination of chemotherapy and targeted therapy to see if it can help people with advanced bile duct cancer feel better and live longer.

  Recruiting Phase 2 Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT06298968

• Combination treatment for advanced gastric cancer

  This study is testing a new combination treatment for people with advanced stomach cancer to see if it helps them live longer and feel better.

  Recruiting Fujian Medical University · Fuzhou, Fujian · NCT06277024

• Combining Pembrolizumab and Lenvatinib for Cervical Cancer Treatment

  This study is testing if a combination of two drugs, pembrolizumab and lenvatinib, can help slow down tumor growth in people with advanced cervical cancer.

  Recruiting Phase 2 University of Texas Southwestern Medical Center · Dallas, Texas · NCT06266338

• Combining radiotherapy and immunotherapy for liver cancer with lymph node metastasis

  This study is testing a new treatment that combines radiation therapy with two medications to see if it helps people with liver cancer that has spread to lymph nodes feel better and have better results than current treatments.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06261125

• Combination of a HER2-targeting vaccine and immunotherapy for advanced endometrial cancer

  This study is testing a new combination treatment for advanced endometrial cancer that includes a personalized vaccine made from patients' own blood, along with other medications, to see if it helps those whose cancer has progressed after other treatments.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06253494

• Treatment options for advanced biliary tract cancer using Pembrolizumab

  This study is testing if the drug Pembrolizumab, alone or with other treatments, can help people with advanced biliary tract cancer live longer and feel better.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06230471

• Combination therapy of Cadonilimab and Lenvatinib for treating unresectable liver cancer

  This study is testing a combination of two drugs, Cadonilimab and Lenvatinib, to see if they can help people with liver cancer who can’t have surgery become eligible for surgery.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06215651

• Neoadjuvant therapy for resectable intrahepatic cholangiocarcinoma

  This study is testing a new combination of chemotherapy and targeted therapy to see if it helps people with a specific type of liver cancer avoid recurrence after surgery.

  Recruiting at 3 sites Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu and 2 other locations · NCT06208462

• Comparing two treatments for advanced liver cancer

  This study is testing if a combination of two treatments for advanced liver cancer can help patients live longer and respond better than just one of the treatments alone.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT06201065

• Combination therapy for patients with unresectable intrahepatic cholangiocarcinoma

  This study is testing a new combination of chemotherapy and targeted therapy to see if it can shrink tumors in patients with a type of liver cancer that can't be surgically removed.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT06192797

• Combination therapy for advanced liver cancer

  This study is testing a new combination of treatments for advanced liver cancer to see if it can shrink tumors enough to make them operable.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT06187961

• Combination treatment for advanced gastric cancer with specific biomarkers

  This study is testing a new combination treatment for people with advanced gastric cancer who have certain biomarkers to see if it helps them live longer without their disease getting worse.

  Recruiting Phase 2 Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT06157996

• Combining cryoablation with Tislelizumab and Lenvatinib for treating solid tumors

  This study is testing a new treatment that combines freezing therapy with two drugs, Tislelizumab and Lenvatinib, to see if it helps people with solid tumors who have already received other treatments.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06032845

• Comparing two treatment combinations for advanced liver cancer

  This study is testing two different treatment combinations for advanced liver cancer to see which one helps patients live longer after their first round of a specific procedure.

  Recruiting Phase 3 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT05985798

• Combining lenvatinib and tislelizumab with RALOX for advanced liver cancer

  This study is testing a new combination of treatments for advanced liver cancer to see if it works better than current options for patients with stage C hepatocellular carcinoma.

  Recruiting Phase 2 Guangdong Provincial People's Hospital · Guangzhou, Guangdong · NCT05954897

• Combining Lenvatinib, Tislelizumab, and TACE for Liver Cancer Treatment

  This study is testing a new combination treatment for liver cancer to see if it can help patients at high risk of their cancer coming back after surgery.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT05920863

• Pembrolizumab plus lenvatinib for recurrent or advanced vulvar cancer

  This study will try pembrolizumab plus lenvatinib for people with recurrent, persistent, metastatic, or locally advanced vulvar cancer that cannot be cured with surgery or radiotherapy.

  Recruiting at 14 sites Phase 2 AGO Research GmbH · Augsburg and 14 other locations · NCT05903833

• Combination treatment for advanced or recurrent thymic carcinomas

  This study is testing a new combination of medicines to see if it can help people with advanced or recurrent thymic carcinomas feel better and manage their cancer more effectively.

  Recruiting Phase 2 National Cancer Center, Japan · Chūō, Tokyo · NCT05832827

• Combination treatment for advanced cholangiocarcinoma

  This study is testing a new combination of four drugs to see if it can help people with advanced cholangiocarcinoma feel better and improve their treatment results.

  Recruiting Phase 3 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT05823311

• CB-103 combined with lenvatinib or abemaciclib for NOTCH-activated adenoid cystic carcinoma

  This study tests whether combining the NOTCH inhibitor CB-103 with either lenvatinib or abemaciclib can slow tumor growth in adults with NOTCH-activated advanced or metastatic adenoid cystic carcinoma.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT05774899

• Combining lenvatinib and pembrolizumab for treating well-differentiated G3 neuroendocrine tumors

  This study is testing if combining two medications, lenvatinib and pembrolizumab, can help people with well-differentiated grade 3 neuroendocrine tumors feel better and improve their treatment outcomes.

  Recruiting Phase 2 University of California, San Francisco · San Francisco, California · NCT05746208

• Combining Lenvatinib, TACE, and Camrelizumab for Advanced Liver Cancer Treatment

  This study is testing a new combination treatment of lenvatinib, TACE, and camrelizumab to see if it helps people with advanced liver cancer live longer compared to using lenvatinib and TACE alone.

  Recruiting Phase 3 West China Hospital · Chengdu, Sichuan · NCT05738616

• Using pembrolizumab and lenvatinib to treat kidney cancer before surgery

  This study is testing if a combination of two drugs, pembrolizumab and lenvatinib, can help treat kidney cancer before surgery to see how well they work together.

  Recruiting Early Phase 1 Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT05733715

• Using Lenvatinib for treating advanced bone and soft tissue sarcomas

  This study is testing if a new medication called lenvatinib can help people with advanced bone and soft tissue sarcomas who haven't had success with other treatments.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan · NCT05617859

• Combining lenvatinib with iodine-125 seed brachytherapy for treating liver cancer

  This study is testing if combining a medication called lenvatinib with a special type of radiation therapy can help people with liver cancer that hasn't improved with other treatments live longer and feel better.

  Recruiting Phase 3 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT05608213

• Combining Lenvatinib, Pembrolizumab, and Radiation Therapy for Advanced Endometrial Cancer

  This study is testing a new treatment that combines two medications and radiation therapy to see if it can help people with advanced endometrial cancer feel better and improve their outcomes.

  Recruiting Phase 1 University of Miami · Miami, Florida · NCT05603910

• Combining Lenvatinib, Tislelizumab, Gemcitabine, and Cisplatin for Advanced Cholangiocarcinoma

  This study is testing a new combination of four cancer drugs to see if it can help people with advanced bile duct cancer feel better and have more treatment options.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT05532059

• Combination treatment for advanced intrahepatic cholangiocarcinoma

  This study is testing if a new combination of medications can help people with advanced liver cancer live longer and feel better compared to standard chemotherapy.

  Recruiting Phase 3 Shanghai Junshi Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT05342194

• Combining lenvatinib and pembrolizumab before surgery for advanced kidney cancer with IVC tumor thrombus

  This study is testing if combining two medications, lenvatinib and pembrolizumab, before surgery can help shrink advanced kidney cancer that has spread to a major vein and improve surgery results.

  Recruiting Phase 2 University of Texas Southwestern Medical Center · Dallas, Texas · NCT05319015

• Combination of pembrolizumab and lenvatinib for liver cancer treatment

  This study is testing whether a combination of two cancer drugs, pembrolizumab and lenvatinib, can help patients with liver cancer have better outcomes after surgery.

  Recruiting at 6 sites Phase 2 University College, London · Birmingham and 10 other locations · NCT05185739

• Combining Lenvatinib and Letrozole for Advanced Breast Cancer

  This study is testing if combining two drugs, lenvatinib and letrozole, can help women with advanced breast cancer that hasn't improved with previous treatments.

  Recruiting Phase 2 National University Hospital, Singapore · Singapore · NCT05181033

• Treatment of advanced endometrial cancer with Envafolimab and Lenvatinib

  This study is testing if a new treatment combining Envafolimab and Lenvatinib can help people with advanced endometrial cancer who haven't had success with regular chemotherapy.

  Recruiting at 19 sites Phase 2 3D Medicines · Beijing, Beijing Municipality and 18 other locations · NCT05112991

• Cryoablation with Sintilimab and Lenvatinib for Liver Metastasis

  This study is testing whether combining a freezing treatment with two medications can help people with hard-to-treat liver cancer feel better after their previous treatments.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05098847

• Combining pembrolizumab and lenvatinib for treating brain metastases in cancer patients

  This study is testing if combining two cancer drugs, pembrolizumab and lenvatinib, can help patients with solid tumors and brain metastases, especially those with triple negative breast cancer or non-small cell lung cancer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05064280

• Cryoablation with Tislelizumab and Lenvatinib for Advanced Liver Cancer

  This study is testing if combining a freezing treatment with two medications can help people with advanced liver cancer feel better and live longer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05057845

• Combining Envafolimab and Lenvatinib for treating advanced solid tumors

  This study is testing if combining two drugs, Envafolimab and Lenvatinib, can help people with advanced solid tumors feel better when other treatments haven't worked.

  Recruiting at 16 sites Phase 1/2 3D Medicines · Bengbu, Anhui and 22 other locations · NCT05024214

• Combining Lenvatinib and Sintilimab for Advanced Liver Cancer After Previous Treatment

  This study is testing if combining two medications, Lenvatinib and Sintilimab, can help people with advanced liver cancer who have already tried other treatments.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05010681

• Evaluating GI-101 with Pembrolizumab, Lenvatinib, or Radiotherapy in Advanced Solid Tumors

  This study is testing a new treatment called GI-101, alone and with other therapies, to see if it can help people with advanced solid tumors.

  Recruiting at 13 sites Phase 1/2 GI Innovation, Inc. · New York, New York and 12 other locations · NCT04977453

• Combination therapy of pembrolizumab and lenvatinib for advanced cervical cancer

  This study is testing if a combination of two drugs, pembrolizumab and lenvatinib, can help patients with advanced cervical cancer who haven't had success with other treatments.

  Recruiting at 3 sites Phase 2 Georgetown University · Washington D.C., District of Columbia and 3 other locations · NCT04865887

• Combination treatment for advanced solid tumors using Trametinib, Everolimus, and Lenvatinib

  This study is testing a new combination of three drugs to see if it can help people with advanced solid tumors, like liver cancer, feel better and improve their condition.

  Recruiting Phase 2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT04803318

• Combining IBI318 and Lenvatinib for advanced lung cancer treatment

  This study is testing a new combination of two drugs, IBI318 and lenvatinib, to see if it can help people with advanced lung cancer who haven't had success with other treatments.

  Recruiting Phase 2 Hunan Province Tumor Hospital · Changsha, Hunan · NCT04777084

• Pembrolizumab plus lenvatinib for HPV-related recurrent respiratory papillomatosis with lung involvement

  This research will try pembrolizumab together with lenvatinib in adults who have HPV-associated recurrent respiratory papillomatosis that involves the lungs.

  Recruiting Phase 2 Yale University · New Haven, Connecticut · NCT04645602

• Neoadjuvant treatment for resectable recurrent liver cancer

  This study is testing if a new combination of immune therapy and medication can help people with resectable recurrent liver cancer have better outcomes after surgery.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT04615143

• Combination of Pembrolizumab and Lenvatinib for Ovarian Cancer

  This study is testing a combination of two medications, pembrolizumab and lenvatinib, to see if they can help women with recurrent ovarian cancer that is sensitive to platinum-based treatments.

  Recruiting Phase 2 Sheba Medical Center · Ramat Gan · NCT04519151

Quick answers

How many clinical trials of Lenvatinib are recruiting right now?

110, as of November 12, 2026. 3 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 17 countries. The most sites are in China (79 trials), United States (15 trials), South Korea (5 trials), Russia (2 trials), United Kingdom (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 76, Phase 3: 10, Phase 1/2: 8, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →